Last update: Aug. 6, 2017


Low Risk for breastfeeding

Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Used in the treatment of hepatitis C, usually in combination with other antivirals.

Since the last update we have not found published data on its excretion in breast milk.

Its pharmacokinetic data (slightly elevated molecular weight and very high percentage of plasma protein binding) make it very unlikely that significant amounts will pass into milk, so that although there is disagreement (Thompson 2016, Spera 2016), other experts believe that treatment with Paritaprevir, on its own or in combination with Ombitasvir and ritonavir or with Ombitasvir, Ritonavir and Desabuvir is not contraindicated during breastfeeding (LactMed 2016).

See below the information of these related products:


We do not have alternatives for Paritaprevir.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Paritaprevir in other languages or writings:


Paritaprevir belongs to this group or family:


Main tradenames from several countries containing Paritaprevir in its composition:

  • Holkira ™. Contains other elements than Paritaprevir in its composition
  • Technivie™. Contains other elements than Paritaprevir in its composition
  • Viekira™. Contains other elements than Paritaprevir in its composition
  • Viekirax™. Contains other elements than Paritaprevir in its composition


Variable Value Unit
Oral Bioavail. 50 %
Molecular weight 766 daltons
Protein Binding 97 - 98,6 %
Tmax 4 - 5 hours
T1/2 5,5 hours


  1. EMA. Ombitasvir-Paritaprevir-Ritonavir. Drug Summary. 2017 Full text (in our servers)
  2. EMA. Ombitasvir-Paritaprevir-Ritonavir. Ficha técnica. 2017 Full text (in our servers)
  3. LactMed. Paritaprevir. Full Record Display. 2016 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM